Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Pacific Biosciences of California Inc’s current trading price is -85.02% away from its 52-week high, while its distance from the 52-week low is 37.50%. The stock’s price range during this period has varied between $1.16 and $10.65. The company, active in the Healthcare sector, saw a trading volume of around 22.71 million for the day, considerably higher average daily volume of 8.95 million observed over the last three months.
The stock market performance of Pacific Biosciences of California Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $10.65 on 12/27/23, while the lowest price during the same time frame was $1.16, recorded on 07/02/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Pacific Biosciences of California Inc (PACB) has experienced a quarterly decline of -0.31% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 375.59M and boasts a workforce of 796 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.7518, with a change in price of +0.2400. Similarly, Pacific Biosciences of California Inc recorded 9,577,482 in trading volume during the last 100 days, posting a change of +17.71%.
How PACB’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for PACB stands at 2.03. Similarly, the long-term debt-to-equity ratio is also 2.01.
PACB Stock Stochastic Average
As of today, the raw stochastic average of Pacific Biosciences of California Inc over the past 50 days is 13.79%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 3.02%. Additionally, the Stochastic %K and %D values for the company were 15.73% and 32.70%, respectively, over the past 20 days.
PACB Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The index has shown a price loss of -83.74% this year. Over the last six months, there has been a stronger performance of -21.04%. The price of PACB leaped by -16.05% during the last 30 days period. For the last 5-days stocks have slided -30.65%.
